SPOTLIGHT: Schizophrenia drugs don't cut aggression

In a journal article sure to fuel the already-fierce debate over antipsychotic drugs, new research shows that placebo may be more effective at managing aggression in intellectually disabled patients. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.